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Studies on autoregulation (AR) of renal blood flow (RBF) in the
ischemic rat kidney. N. Lameire, B.P. Smollich, D. Kesteloot, L.
Deridder, Departments of Medicine and Histology, University of Ghent
(Belgium) and Rostock, German Democratic Republic. Ketanserin (K)
is a new antagonist of serotonin (S), a known renal vasoconstrictor (VC)
in the rat. This study was designed to determine whether K was able to
affect the loss of AR of RBF after renal ischemia, produced by
unilateral artery clamping for 40 mm. Regression lines (RL) of RBF to
renal perfusion pressure were determined before ischemia (RL1), before
K and after 48 hrs or 7 days of reperfusion (RL2) and during K infusion
(RL3). Before ischemia, all kidneys showed perfect AR. After both 48
hrs and 7 days, RL2 was significantly different from RL1 (P < 0.001),
indicating loss of AR of RBF. Renal histology showed severe histologic
lesions of the renal vessels and epithelium. With K, a perfect restora-
tion of AR was observed both at 48 hrs and 7 days (RL3 not different
from RL1, but different from RL2, P < 0.001). Dose-response curves to
intrarenal S indicated an enhanced VC in the ischemic compared to
normal kidneys. K was not only able to prevent this VC but to produce
a net renal vasodilation. In conclusion, the loss of AR of RBF can be
restored by an S antagonist, pointing to a possible role of S in the
abnormal renovascular response to ischemia.
Acute infusion of a converting enzyme inhibitor (CEI) reveals an
increased post-glomerular resistance in a rat strain susceptible to the
development of glomerulosclerosis (GS). P.J. Westenend, J.F.M. Smits,
H.A.J. Struyker-Boudier, J.J. Weening, Departments of Pathology and
Pharmacology, University of Leiden, Maastricht and Groningen, The
Netherlands. In a previous study we showed an increased incidence of
GS lesions with aging in intact male rats of the normotensive Wistar
Zeist (W) strain as compared to the Wistar Kyoto (WKY) strain (3 3%
vs. 0 0% at the age of 11 months). GS was accelerated by unilateral
nephrectomy (UN) at the age of 3 months (15 13% in W vs. 0 0%
in WKY). Functional studies one month after operation demonstrated a
comparable increase in GFR in both strains (W, 0.9 0.4 [sham] vs. 1.5
0.3 ml/min [UN], P <0.05; and WKY, 0.9 0.2 [sham] vs. 1.5 0.3
mi/mm [UN], P < 0.05). Filtration fraction (FF) was increased in the W
rat subjected to UN (0.18 0.06 vs. 0.29 0.07, P < 0.05) but not in
the WKY rat (0.21 0.06 vs. 0.20 0.07), suggesting an increased
post-glomerular resistance in W. To test this hypothesis, rats of both
strains were subjected to intravenous bolus injections of increasing
doses of a CE! (1, 3 and 10 mg/kg Captopril). The effects on renal
function were determined using an electromagnetic flow probe for
continuous RBF measurement, a pressure transducer for direct blood
pressure measurement and inulin clearance for GFR. Total renal
vascular resistance (RVR) and FF were calculated. Even at 10 mg/kg
the effect on blood pressure was marginal (W, —9 7% [sham] vs. —2
2%; WKY, 0 8% [sham] vs. —4 16% [UN]). The maximum effect
on RVR and FF was already obtained at 1 mg/kg.
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RVR —21 7% —16 8% —16 7% —13 3%
FF —43 15% —51 26% —17 20% —22 8%
a P < 0.05, W compared to WKY.
Both strains show a comparable response of the RVR to CE!. However,
the response in FF is more pronounced in W rats as compared to WKY
rats and not proportionate to the response in RVR in W. We conclude
that: (1) acute CE! reveals an increased post-glomerular resistance in
the GS susceptible W strain indicating that glomerular pressure is
increased; (2) resistance to GS in WKY is associated with an attenuated
response to acute CE! compatible with a relatively low post-glomerular
resistance; and (3) acute CE! may be helpful in recognizing genetic
susceptibility to the development of OS.
Short-term renal hemodynamic effects in pre-dialysis patients treated
with recombinant human erythropoietin. L.A.M. Frenken, J.F.M. Wet-
zels, H.E. Sluiter, G. Schrjjver, R.A.P. Koene, Department of Medi-
cine, Division of Nephrology, University Hospital Njjmegen, The
Netherlands. Recombinant human erythropoietin (r-HuEPO) is an
effective treatment for the anemia of chronic renal failure. The rise of
hematocrit (Ht) and blood viscosity might accelerate the progression of
renal failure by an increased renal vascular resistance and glomerular
capillary pressure. Therefore, we studied baseline GFR (inulin clear-
ance) and ERPF (PAH clearance) before (Ht 0.24 [0.05] liter/liter) and
after eight weeks of r-HuEPO treatment (Ht 0.39 [0.031 liter/liter; P =
0.001) in eight pre-dialysis patients (age 25 to 66 years). GFR and ERPF
were measured using standard techniques. We also studied the acute
hemodynamic responses to Captopril (CTP), 25 mg orally after baseline
values were obtained. After eight weeks of treatment we did not
observe significant changes in baseline GFR, filtration fraction (FF),
renal blood flow (RBF), fractional excretion of albumin (FEAIb), or
mean arterial blood pressure (MAP).
Before r-HuEPO therapy After 8 weeks
Baseline After CTP Baseline After CTP
ERPF mI/mm 43.0 (24.0) 53.6 (28.4)a 35.8 (17.8) 35.8 (18.9)
GFR mI/mm 8.2 (3.0) 9.5 (3.4) 7.4 (2.9) 7.1 (3.2)
FF % 21.2 (7.7) 19.2 (6.4)a 22.3 (6.0) 20.9 (4.6)
RBF ml/min 57.6 (32.5 71.3 (37.8)a 58.4 (27.5) 59.1 (29.1)
FEAIb % 0.45 (0.40) 0.39 (0.33)a 0.64 (0.50) 0.58 (0.44)
MAP mm Hg 111.5 (23.3) 103.3 (2l.9)a 110.3 (15.8) 103.7 (16.6)a
Data are mean values (SD).
a P < 0.05 vs. baseline
Before r-HuEPO, Captopril caused a significant increase of RBF, and a
decrease of FF and FEAIb. These responses were absent after correc-
tion of Ht. The disappearance of a renal hemodynamic response to
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Captopril, when Ht increased to liter/liter, might indicate the
occurrence of adaptive efferent vasodilation, attenuating an effect of
increased blood viscosity on renal blood flow. An additional benefit of
Captopril with regard to hyperfiltration can therefore not be expected in
these patients.
Atrial natriuretic peptide (ANP) shifts the abnormal diurnal sodium
rhythm in essential hypertension (EH) towards normal. W.M,T. Janssen,
D. de Zeeuw, G.K. van der Hem, P.E. de Jong, Division of Nephrol-
ogy, State University Hospital Groningen, The Netherlands. In EH
urinary sodium excretion (UNaV) has a diurnal rhythm with a maxi-
mum 3 hours earlier than in normotensives. In contrast, the rhythms of
mean arterial pressure (MAP) and potassium excretion (UKV) are
normal in EH. ANP may play a role in the abnormal renal sodium
handling in EH. Therefore, we studied the effect of a 5-day, 0.2 g/min
ANP infusion on the rhythms of the excretion of these and other
solutes, MAP, GFR, and plasma ANP (pANP) using the cosinor-
method in 6 patients with EH (Table). They were 6 weeks without
medication, kept at bedrest during 3 equilibration, 3 baseline, 5 ANP-
infusion, and 3 recovery days, and adhered to a rhythm diet with equal
amounts of fluid, sodium, and potassium every 4 hours. During baseline
all parameters, except pANP, had significant rhythms: the rhythms of
UNaV and UChIV were abnormal, and the rhythms of UKV and MAP
were normal, as expected. However, during ANP a time-shift towards
normal was found in UNaV and UChJV rhythms in all EH. In contrast,
UKV and MAP rhythms were not affected by ANP. Moreover, only the
rhythms of those solutes were changed whose 24-hour excretion also
was changed by ANP infusion. The Table shows the hours of maximum
values of the diurnal rhythms (P < 0.05 vs. control).
Maximum SEM (hr) Baseline ANP Recovery
Sodium 11.9 1.3 14.6 0.6a 10.9 1.2
Chloride 11.5 1.1 13.3 0.8k 11.0 1.0
Potassium 12.1 0.7 12.4 0.6 11.4 0.8
Calcium 8.8 0.7 10.5 0.7k 10.2 1.1
Phosphate 20.3 0.8 19.5 0.4 19.4 1.2
Uric acid 11.3 0.8 11.3 0.5 10.8 0.9
MAP 16.3 0.5 16.4 0.8 15.8 0.5
GFR 12.5 0.7 12.5 1.8 11.8 0.8
Individual shifts in UNaV correlated (r = 0.94, P < 0.01) with pANP
during ANP. During ANP maximum UNaV correlated (r = 0.83, P <
0.05) with maximum MAP, whereas this relation was absent before
ANP infusion. These data suggest a specific role for ANP in the
abnormal renal sodium handling in EH.
Effects of atrial natriuretic factor (ANF) on distal tubule function in
man. A.J. Rabelink, H.A. Koomans, E,J. Dorhout Mees. Department
of Nephrology, University Hospital Utrecht, The Netherlands. Exper-
imental studies have indicated that ANF inhibits sodium reabsorption in
the distal nephron. This effect is supposed to be limited to the inner
medullary collecting duct. Data on the effects of ANF in the human
distal nephron are not available. We studied interactions between ANF
(0.02 g/kg/min) with acutely administered drugs acting in the distal
nephron: amiloride (AMI, 15 mg orally), aldosterone (ALD, 0.5 mg/hr
i.v.) and its antagonist canrenoate (CAN, 200 mg orally) in 6 water-
loaded healthy subjects. The tests were performed as four clearance
studies, separated by at least three days, while the subjects were in
sodium balance (100 mmol Na/day). ANF alone increased natriuresis
(j.mol/min), fractional lithium excretion (FELl, %), and dilutingsegment
delivery, estimated from maximal free-water clearance, and decreased
diluting segment reabsorption. AMI and CAN decreased, and ALD
increased sodium reabsorption without affecting proximal reabsorption
parameters. During AMI and CAN, ANF increased sodium excretion
further. This effect was additive and not potentiated. This indicates that
AMI and CAN act partly onthe same nephron segments as ANF. ANF
abolished much of the antinatriuretic effect of aldosterone. This also
indicates that ANF and ALD act partially on the same distal segment.
Since the major antinatriuretic action of aldosterone is located in the
cortical collecting tubules, this would implicate an action of ANF also
in this segment. Remarkably, in neither of these experiments was the
natriuresis of ANF accompanied by a kaliuresis, despite increased
distal delivery, suggesting that ANF interacts with potassium secretion
in the distal nephron.
Control AMI
-ANF +ANF -ANF +ANF
UNaV
UKV
FELl
Uom
124 27
133±13
26±2
61±3
281 83
81±8
28±2
67±5
361 48
54±7
26±2
79±3
467 83
47±8
29±1
79±4
CAN ALD
-ANF +ANF -ANF +ANF
UNaV
UKV
FELl
Uom
181 24
88 15
25±2
75±6
360 67
63 11
29±2
78±5
24 7
118 14
27±2
60±5
215
107 15
32±3
62±5
Cytotoxic effects of commercial CAPD fluids and of bacterial exoprod-
ucts on human mesothelial cells in vitro. H. van Bronswjk, H.A.
Verbrugh, H.J. Bos, E.C.J.M. Heezius, P.L. Oe, J. van derMeulen, J.
Verhoef, Free University Hospital, Amsterdam and State University
Utrechi, The Netherlands. Human mesothelial cell monolayer cultures,
derived from surgically removed omentum, were exposed to peritoneal
dialysis fluids, to supernatants from cultures of Staphylococcus aureus
and S. epidermidis and to antibiotics. The identity of mesothelial cells
was confirmed by the presence of an intracellular cytoskeleton and by
their aspect on electron microscopy. The cytotoxicity of various agents
for the cultured mesothelial cells was measured by a 51 Cr-release
assay. All brands of fresh peritoneal dialysis fluids induced a more than
50% 51 Cr-release after 18 hr. Morphological changes observed in-
cluded retraction and shrinking of cells, pyknosis of the nuclei and
finally detachment of the cells over an 18 hr period. Neutralization of
the acid (pH 5.2 to 5.5) fluids to pH 7.3 did not abolish the cytotoxicity.
In contrast, effluent dialysis fluids were not toxic for mesothelial cells;
neither was acid (pH 5.5) culture medium nor culture medium with
glucose up to 2%. However, higher glucose concentrations induced
increasing 51 Cr-release. Furthermore, filter-sterilized supernatants of
S. aureus were cytotoxic for mesothelial cell monolayers in 4 out of 7
(57%) strains of S. aureus tested, In contrast, only 4 out of 29 (14%)
strains of S. epidermidis produced cytotoxic exoproducts (P = 0.03).
Antibiotics were not found to be cytotoxic, with the possible exception
of erythromycin. We conclude that currently available peritoneal dial-
ysis fluids are cytotoxic for human mesothelial cells in vitro, and that
during episodes of peritonitis exoproducts of some bacterial strains may
further reduce mesothelial cell viability.
HIV infection in patients on renal replacement therapy, 1985—1988 data
from the EDTA registry. W. Geerlings, W. Fassbinder, F.P. Brunner,
Department of Nephrology, State University Hospital, Groningen, The
Netherlands and EDTA Registry. In 1985 the center questionnaire of
the registry of the European Dialysis and Transplantation Association-
European Renal Association (EDTA/ERA) contained for the first time
questions regarding policy towards HIV testing and number of HIV+
patients. In 1987 81.9% of the 2.154 centers in 33 countries returned
these questionnaires. The number of centers reporting testing for HIV
inall patients increased from 30% in 1985 to 75% in 1988. The number
of HIV+ patients increased from 127 in 1985 to 277 in 1987. Of these,
in 1986 20 patients and in 1987 29 patients newly developed AIDS or
AIDS related symptoms. All centers reporting anti-HIV+ positive
patients in 1987 received a detailed, anonymous questionnaire contain-
ing questions on route of infection, reason for testing, tests used,
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method of renal replacement therapy (RRT), age and sex. In 1989 these
centers received a follow-up questionnaire. Of the returned question-
naires in 1988 127 could be analyzed. Analysis revealed that age
distribution differed strikingly from distribution of AIDS in the normal
population. Prevalence of anti-HIV+ patients on RRT was equally
distributed in all age groups and in both sexes. The suspected route of
infection in 57% proved to be transfusion of blood or blood products. In
17% grafting was the suspected route of infection. Other reasons
(homo/bisexual male, heroin addiction, hemophiliac, a.o.) added up to
25% of suspected routes of infection. No infection was reported that
could be attributed to the dialysis procedure. Haemodialysis as mode of
treatment (MOT) increased from 67% at the time of HIV contraction to
80% in 1988, with a concomitant decrease of graft as MOT from 24% to
10%, thus showing a considerable loss of functioning grafts. None of the
originally reported HIV+ patients was grafted in 1988. Twenty-five
percent of patients died in 1987, and in 1988 a 23% mortality was
reported.
Renal extraction of creatinine: Additional evidence for tubular secre-
tion of creatinine in man. M.A.G.J. ten Dam, A.A. Bouman, R.W. ten
Kate, A.J.M. Donker, Department of Internal Medicine and Clinical
Chemistiy, Free University Hospital, Amsterdam, The Netherlands. A
reliable estimate of glomerular sieving coefficients (GSC's) of circulat-
ing macromolecules can be obtained by measuring their fractional
extraction, that is, the ratio between the renal extraction of the solute
and the renal extraction of a freely filtered molecule. The use of
creatinine as freely filtered marker would be convenient; however,
tubular secretion and the presence of non-creatinine chromogens in
plasma may influence creatinine extraction. Therefore, renal extraction
of creatinine was compared with renal extraction of inulin. In 9 patients,
undergoing elective heart catheterization, serum samples were obtained
simultaneously from the right renal vein and the aorta five to ten
minutes after an i.v. bolus injection of 15 ml 25% solution of inulin
(Inutest'). Creatinine was measured with a colorimetric (Jaffé) method
and with an enzymatic (MPA) method. Non-creatinine chromogens
were calculated from the difference between Jaffé creatinine and MPA
creatinine. Results: renal extraction in %:
Mean SD Range
Inulin 21±4 16—26
Creatinine MPA 24 3 18 —31
Creatinine Jaffé 17 5 10—25
Chromogens —18 7 —71—9
The extraction of creatinine MPA was significantly higher than the
inulin extraction (P < 0.02) most likely reflecting tubular secretion of
creatinine. The extraction of chromogens, representing 16% of Jaffé
creatinine in the arterial serum, was not significantly different from 0.
This provides an explanation for the low extraction of Jaffé creatinine
compared to the inulin extraction (P < 0.02). We conclude that for an
accurate estimation of a GSC with the fractional extraction method,
inulin should be used as freely filtered marker.
Influence of sodium intake on renal fractional lithium excretion and
erythrocyte sodium-lithium countertransport in normotensive volunteers.
L.D. Elving, B. Roszek, H.G.P. Swarts, J.F.M. Wetzels, E. de Nobel,
J.J.H.H.M de Pont, J.H.M. Berden, Department of Medicine, Divi-
sions of General Internal Medicine and Nephrology, and Department
of Biochemistry, University of Nmegen, The Netherlands. Recent
studies have suggested that sodium-lithium countertransport (NaLiCT)
in erythrocytes is a marker for hypertension and development of
diabetic nephropathy. In hypertensive patients NaLiCT is increased
and inversely related with fractional lithium excretion (FEL; a marker
for proximal tubular sodium transport). To evaluate the effect of dietary
sodium on NaLiCT and its relation with FEL, we studied NaLiCT and
FELl in 10 healthy, normotensive volunteers on a high (12 g/day) and
low (3 glday) sodium diet, in a randomized cross-over study. Each diet
was kept for one week, with an interval of one week with normal
sodium intake. NaLiCT was measured after pre-incubation of the red
cells with lithium bicarbonate instead of lithium chloride, which re-
duced loading time from 3 hr to 20 mm. Normal values for NaLiCT are
239 57 mol/liter cells/hr (mean SD). The intra-assay variation is
8.6% and the inter-assay variation is 13%. On the last day of each
dietary period, 2-hour FEL, and FENa were measured together with
NaLiCT. Creatinine clearance was used as a marker for glomerular
filtration rate. FEL was measured after ingestion of 600 mg lithium
carbonate on the previous evening. In a separate set of experiments it
was shown that ingestion of 600 mg lithium carbonate did not alter
NaLiCT. Urinary sodium excretion was 27 12 and 245 41 mmol/24
hr (mean SD) during low and high sodium intake, respectively. FeNa
and FELl were significantly higher on the high sodium diet, whereas
NaLiCT was not different (Table).
Low sodium High sodium
NaLiCT .unol/l 257 55 243 38
cells/hr
FENa% 0.28 0.17 1.06 0.3la
FELI% 25.0 5.5 32.5 14.?
Values are mean SD a P < 0.01.
A positive correlation between FELl and FENa existed during both low(r = 0.64; P < 0.05) and high sodium intake (r = 0.65; P < 0.05). No
significant correlation was found between NaLiCT and FELl or FENa. It
is concluded that in normotensive volunteers erythrocyte sodium-
lithium countertransport is not influenced by dietary sodium intake and
is not correlated with fractional lithium excretion.
11MG CoA reductase inhibition decreases low density lipoprotein
cholesterol (LDL-C) and triglycerides (TG) in female analbuminemic rats.
J.A. Joles, N. Willekes-KoolschUn, A.J. Rabelink, D.W. Erkelens, A. v.
Tol. Departments of Nephrology and Internal Medicine, University
Hospital, Utrecht, and Department of Biochemistry I, Erasmus Uni-
versity, Rotterdam, The Netherlands. In the nephrotic syndrome (NS)
hypoalbuminemia is associated with hypercholesterolemia. HMG CoA
reductase inhibition is effective in reducing LDL-C in patients with NS
(Lancet ii, 1335, 1988). The female Nagase analbuminemic rat (NAR),
when fed a standard diet and compared to the control Sprague-Dawley
rat (SDR), displays very high (P < 0.01) cholesterol (6.1 0.3 vs. 2.5
0.1 mM) and TO (6.1 0.6 vs. 1.3 0.2 mM) levels. We studied the
effect of 4 weeks of HMG CoA reductase inhibition with simvastatin
(0.5 to 1.0 mg/kg/day), infused with a s.c. osmotic pump (Alzet' 2ML4),
on plasma lipoproteins by density gradient ultracentrifugation and
apolipoproteins (apo) Al and B by electroimmunoassay, in NAR fed a
semi-synthetic diet.
Strain (n)
Control Simvastatin
NAR (6)NAR (5) SDR (3)
Cholesterol mM 9.5 0.9" 2.5 0.1 4.8 0.6a
LDL-cholesterol mw 5.3 0.5' 1.2 0.1 2.9 0.4a
HDL-choelsterol mc 3•5 03b 1.1 0.2 1.5 0.2
Triglycerides mM 4.2 0•5b 0.9 0.1 1.3 o.l
apo Al mg/IOOml 126 33" 22 2 40 8
apoB%reltostd l61±6' 76±9 159±8
a p < 0.01 control vs. simvastatinbP < 0.01 NAR vs. SDR
The semisynthetic diet, as compared to the standard diet, caused a
further increase (P < 0.01) in plasma cholesterol in NAR but not in
SDR. In NAR on the latter diet HMG CoA reductase inhibition with
simvastatin caused an important decrease in plasma cholesterol, LDL-
C, HDL-C, TG, apo Al, but no change in apo B. This suggests that the
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main effect of simvastatin in the analbuminemic rat may be via a
decrease in the synthesis of liver lipoproteins rather than in an increase
in their catabolism.
Diagnostic value of anti-neutrophil cytoplasmic autoantibodies and
other parameters in diagnosis and follow-up of Wegener's granulomato-
sis. C. Halma, M.R. Daha. E. Schrama, J. Hermans, L.A. van Es, F.J.
van der Woude. Department of Nephrology, University Hospital Lei-
den, The Netherlands. The presence of anti-neutrophil cytoplasmic
autoantibodies (ANCA) detected by indirect immunofluorescence (IF)
has been reported to have a very high sensitivity for the diagnosis of
Wegener's granulomatosis (WG) and related diseases. In addition, titers
of IF are thought to closely reflect disease activity. In a retrospective
series of 379 sera the positive predictive value of IF for the diagnosis of
WG was 89%. There were 6 false-positive results of IF in a series of 80
control sera of patients with glomerulonephritis and various autoim-
mune diseases (specificity 93%). In 23 patients disease activity was
correlated with ANCA, assayed by IF and Elisa; with rheumatoid
factor measured in an isotype specific Elisa; and with erythrocyte
sedimentation rate (ESR). All parameters were significantly higher in
patients with active disease (ACT). False-negative results of IF were
seen in 17% of patients with ACT. Positive results or increasing values
of these parameters were of very limited value in predicting ACT. The
highest positive likelihood ratio for ACT was provided by the combi-
nation of IF and ANCA-Elisa (4.3). Thus, the decision to treat a patient
for a presumed relapse should not be based on serological data only. An
ESR <15 mm virtually excluded ACT, especially when one or more
other parameters were negative, The negative likelihood ratio for a
negative IF result was 0.3. Therefore, the ESR remains the most useful
test to exclude ACT.
Value of serum aluminum monitoring in dialysis patients. P.C.
D'Haese, J.P. Clement, M.M. Elseviers, L.V. Lamberts, F.L. Van de
Vyver, M.E. De Broe. Department of Nephrology-Hypertension, Uni-
versity of Antwerp, Belgium, The clinical relevance of regular serum
aluminum (SAl) monitoring in dialysis patients (N = 1238) was inves-
tigated in a retrospective ('84 to '87) multi-center (N = 15) study by
six-monthly determination of the SAl. SAl was determined by atomic
absorption. Laboratory performance was assured by monthly partici-
pation in an external quality control program. Al levels in water and
dialysate were below 6 sg/liter in all participating centers. During the
study period a steady decline of the overall mean SAl from 52 61.4
pg/liter down to 28.9 38.8 pg/liter was observed. Concomitantly with
the decrease of SAl a significant reduction of the prescribed dose of
Al(OH)3 was noted. Serum phosphorus levels did not change signifi-
cantly (52 mg/liter vs. 55 mg/liter). Compared to a control dialysis
population (SAl 39.3 41.1 ag/liter; N = 240), patients with overt liver
disease (N = 19) and dialysis encephalopathy (N = 6) showed signifi-
cantly (P < 0.001) higher SAl levels, being 59.5 62.8 and 165.5
136.2 pg/liter, respectively. Not a single patient with a serum ferritin
above 1000 ng/ml had a SAl level in excess of 100 sg/liter. In a parallel
study bone Al content and histological and histochemical findings were
correlated with SAl in 78 dialysis patients. In this group 25% of the
patients showed the combination of histological features of osteomala-
cia and a positive aluminon' staining. SAl levels of patients with
Al-induced bone disease (AIBD) were significantly higher compared to
those observed in patients without AIBD (159.7 199.6 vs. 39.9 29.5
sg/liter, P < 0.001). The sensitivity and specificity of a SAl> 50 pg/liter
were respectively 75 and 80% in the detection of Al-overload (that is,
bone Al > 15 pg/g), and 81 and 74% in the diagnosis of AIBD. It is
concluded that, provided the analyses are performed by a qualified lab,
regular serum Al monitoring: (i) increases the alertness of the clinican;
(ii) may change the policy of phosphate binding therapy; (iii) serves as
an important indicator of possible Al-overload/toxicity.
Citrate anticoagulation in chronic hemodialysis. J.van der Meulen, R.
Statius van Eps, L.M. Faber, P.J.M.J.de Vries, P.L. Oe, A.J.M.
Donker, Dialysis Unit, Free University, Amsterdam, The Netherlands.
Hemodialysis with heparin (H-HD), even when it is reversed by
protamine, causes a 10 to 30% incidence of hemorrhagic complications
in patients with acute renal failure and who are at risk for bleeding.
Instead, regional citrate anticoagulation (C-HD) has been advised to be
used in these patients. This study evaluates how far C-HD can be used
in chronic hemodialysis. Six patients, who started bleeding while on
maintenance H-HD, were transfered to C-HD. This was performed by
infusing 15% trisodium citrate at a rate of 168 mI/hr into the arterial line.
By this the whole blood clotting time was prolonged to more than 20
mm. Calcium-free dialysate was used to avoid higher citrate require-
ments and 5% calcium chloride was supplemented at a rate of 30 mol/hr
into the venous line. Before and after 4 weeks C-HD, blood samples
were obtained from the arterial line pre- and postdialysis. Furthermore,
body weight, blood pressure and complaints were registered. Results
expressed in mean SD are summarized in the table.
H-HD C-HD
Pre Post Pre Post
Sodium 138 2.4 138 2.1 139 3.0 138 2.4
mmol/liter
Urea 32.1 8.3 13.3 5.6 30.4 6.7 11.1 l.8a
mmol/liter
Calcium 2.22 0.17 2.71 0.19a 2.25 0.19 2.30 0.33
mmol/liter
pH 7.38 0.03 7.41 O.O4' 7.39 0.03 7.49 0.04
Bicarbonate 22.2 1.4 23.6 3,1b 25.2 4.0 29.8 2.2a
mmol/liter
Weight change 3.7 41b 1.7 0.5
kg
a Significant difference between pre- and postdialysis P < 0.05b Significant difference between H-HD and C-HD P < 0.05
In all six patients bleeding stopped and did not recur during C-HD.
However, two patients experienced severe cramps at the end of the four
weeks and in all patients pH and bicarbonate increased significantly
(Wilcoxon test) during C-HD. Perhaps the metabolic alkalosis by citrate
has contributed to these cramps. Thus, for chronic C-HD the dialysate
should not only be devoid of calcium but also the acetate concentration
should be reduced by at least 4 mmol/liter.
Staphylococcus epidermidis resistant to methicillm and/or cephalospo-
rins: an increasing problem in CAPD.peritonitis? E. W. Boeschoten,
P.J.G.M. Rietra, D.G. Strujjk, R.T. Krediet, L. Arisz, Academic
Medical Centre, Amsterdam, The Netherlands. Peritonitis is still con-
sidered to be an important complication of CAPD. Most of the
peritonitis episodes are caused by coagulase negative Staphylococci,
especially Staph. epidermidis, 20 to 50% of them being reported
resistant to methicillin and/or cephalosporins. To analyze whether
resistance to methicillin and/or cephalosporin is an increasing problem
in CAPD, we studied all 158 Staph. epidermidis strains cultured in 280
successive episodes of peritonitis that occurred in 79 CAPD-patients
during a six year period. During this period cephradine was the
treatment of first choice for peritonitis. Resistance to methicillin was
tested with a disc-diffusion technique with Isosensitest agar (oxoid) and
Neo-sensitabs at 30%. Zone diameters more than 25 mm were inter-
preted to represent adequate susceptibility corresponding with a MIC of
4 üml. Diameters less than 20 mm were interpreted as resistant
corresponding with a MIC of more than 16 p/mI. Sensitivity to
cephradine was tested at 37CC. During the six years studied the
percentage of Staph. epidermidis being resistant to methicillin and/or
cephalosporins did not change and was 32 6% (40% in the first year,
22% in the second year, 31% in the last year). Furthermore, in the
individual patient the occurrence of methicillin and/or cephalosporin
resistant Staph. epidermidis in a previous episode did not predict
resistance to these antibiotics in a following peritonitis episode in the
same patient. Thirty-three episodes caused by methicillin/cephalospo-
rim resistant Staph. epidermidis were followed by another peritonitis
episode in which the Staph. epidermidis was involved. Of these 33
strains, 17 were sensitive to methicillin/cephalosporin. We conclude
that there is no indication for increasing resistance to methicillin and/or
cephalosporins of Staph. epidermidis in CAPD peritonitis.
Abstracts 187
Cytochemical detection of cyclosporine nephrotoxicity in human al-
lografts. GA. Verpooten, F. Roels, I. Wybo, M.E. De Broe, Depart-
ment of Nephrology-Hypertension, University of Antwerp; and Depart-
ment of Anatomy, Free University Brussels, Belgium. On the basis of
earlier results in cyclosporine treated rats cytochemical stains were
applied to biopsies of kidney allografts. Cyclosporine toxicity was
diagnosed retrospectively in 5 cases (amelioration of graft function after
diminishing or discontinuing cyclosporine administration). Other biop-
sies were taken 1 hour after surgery (5 cases) or were classified as
rejection in 4 cases (favorable response to steroid administration or
complete rejection). After fixation in 2% glutaraldehyde cryostat sec-
tions were stained with I) Oil Red 0 in isopropanol 2) diaminobenzidine
+ Mn + cytochrome c for cytochrome oxidase. Mononuclear intersti-
tial infiltrate was evident in the rejection cases and also in 3 of 5
cyclosporine toxicity cases. Fat was seen focally in all transplant
biopsies. When the amount of fat was scored from 1 + to 6+, it was
significantly increased in the cyclosporine toxicity cases (P < 0.05;
Mann-Whitney U test). For cytochrome oxidase three staining intensi-
ties are distinguised in normal cortical tissue (the proximal, distal,
collecting tubule). Focally decreased cytochrome oxidase activity was
present in all the cyclosporine toxicity cases and all the rejection cases.
The number of tubular sections with decreased staining were scored.
The loss of cytochrome oxidase was significantly more pronounced in
the cyclosporine toxicity cases as compared to the rejection cases (P <
0.002). When both parameters are plotted overJap of the toxicity cases
and other patients is limited to one case.
Cytomegalovirus infection directly induces MHC class I but not class H
expression on endothelial cells and proximal tubular epithelial cells. W. T.
van Dorp, E. Jonges, C.A. Bruggeman, M.R. Daha, L.A. van Es and
F.J. van der Woude, Department of Nephrology, University Hospital
Leiden and Maastricht, The Netherlands. In clinical renal transplanta-
tion there is an association between cytomegalovirus (CMV) infection
and transplant rejection. We studied MHC expression on cultured
human umbilical cord endothelial cells and proximal tubular epithelial
cells after CMV infection. The MHC expression was investigated using
double antibody radioimmunoassay and immunofluorescence flow cy-
tometry. After CMV infection there was an increase of class I and J2
microglobulin (/32M) expression. This increase corresponded with the
percentage of cells that were infected with CMV. The increase class I
expression was not due to soluble factors produced by the infected
cells. Class I and f32M after CM V-infection expression exceeded that
induced by an optimal concentration of a-interferon. Class II expres-
sion did not increase after CMV infection. However, the gamma-
interferon-induced increase in class II expression was not inhibited by
CMV. It is known that type I interferon inhibit the gamma-interferon
class II upregulation. These results therefore demonstrate that cyto-
megalovirus infection directly upregulates MHC class I but not class II
expression on endothelial cells and proximal tubular epithelial cells.
Cytokines or other humoral mediators do not play a role in this
phenomenon.
De novo and recurrent membranous nephropathy in renal allografts.
A. Kroon, J.F.M. Weizels, K.J.M. Assmann, A.J. Hoitsma, J.H.M.
Berden, Division of Nephrology and Department of Pathology, Univer-
sity Hospital, Nmegen, The Netherlands. We retrospectively exam-
ined renal transplant biopsies in 978 consecutive renal transplants
performed in our institute between 1973 and 1989. We found 13 cases of
membranous nephropathy (MN) and found a de novo manifestation in
10 and a recurrence of the original disease in 3. In the investigation
period seven patients with a definite diagnosis of MN as their original
disease were transplanted. In three patients MN recurred, indicating a
recurrence rate of 43%. In these patients nephrotic range proteinuria
(NRP) occurred 5.7 4.6 months after transplantation. At present two
patients have a normal renal function at 5 and 30 months after
transplantation, whereas one patient died after cardiac surgery 50
months after transplantation with a near normal transplant function. In
the 10 patients with de novo MN, NRP occurred 14.9 16.2 months
after transplantation (range 2 to 57 months). In these patients we
noticed a high incidence of ureteral obstruction (UO) necessitating
urological reintervention (5 out of 10 patients). In the investigation
period 103 transplant patients developed UO, for which surgery was
indicated. Five of them developed a de novo MN, whereas the other 5
cases of de novo MN came from the remaining group of 875 transplant
recipients without UO (Chi-square 16.7; P < 0.0001). This suggests an
association between post-transplant UO and development of de novo
MN. The onset of NRP in de novo MN with UO was earlier after
transplantation (mean 12.2 4.9 months; range 5 to 17) than in those
without UO (mean 17.6 23.3 months; range 2 to 57). The mean
interval between UO and onset of NRP was 6.8 5.4 months. Seven
out of these ten patients developed ESRD (4 with previous UO, and 3
without previous UO). The rate of deterioration of transplant function
was faster in patients with de novo MN and UO (start of dialysis 18.8
15.5 months after onset of NRP) than in patients with de novo MN
without UO (41.0 47.9 months). Out data suggest that MN is not an
uncommon finding after transplantation. The rate of recurrence of MN
is surprisingly high, but none of the patients developed renal insuffi-
ciency until now. Ureteral obstruction seems to be an important factor
in the development of de novo MN. Development of de novo MN after
transplantation was frequently associated with graft failure.
Specific localization of intestinal alkaline phosphatase in the S3 segment
of the human proximal tubule and its release into urine. G.F. Verpooten,
G.D. Nuyts, M.E. De Broe, Department of Nephrology-Hypertension,
University of Antwerp, Antwerp, Belgium. A specific monoclonal
antibody (1AP250) raised against human intestinal alkaline phosphatase
(lAP) was developed and was used to study the expression of this
isoenzyme in human renal tissue and its release into urine. Biochemical
measurements of LAP were performed using an enzyme antigen immu-
noassay (EAIA). At the transition between cortex and medulla, approx-
imately 25% of the total renal alkaline phosphatase was of the intestinal
type. Immunohistochemical examination revealed that lAP was found
exclusively on the brush border of tubuloepithelial cells in the S3
segment of the proximal tubule in the medullary rays and in the outer
stripe of the outer medulla. Isolation of this lAP yielded a sialylated
dimeric enzyme (Mr 140,000). In urine, lAP is released as a partly
hydrolyzed enzyme (Mr 83,000) no longer sensitive to neuraminidase
treatment. Provided that a stabilization buffer is added to urine, LAP can
accurately be dosed on its enzymatic activity using the same EAIA. It
was found that approximately 50% of the urinary AP activity in healthy
persons was of the intestinal type. A sandwich-ELISA system was
developed to be able to detect also the enzymatically inactive (as well
as active) molecules of lAP in urine samples. The immunoreactive/
enzymatically active LAP ratio amounted to 2.1 0.5. The lAP!
creatinine ratios remained quite constant in time in 20 individuals,
suggesting an upper limit around 1.0 to 1.5 IU/g. Recent research
demonstrated that in transplant patients being treated with cyclospo-
rine, there was a rough correlation between the serum cyclosporine
levels and the urinary IAP/creatinine concentrations. In neutropenic
patients being treated with aminoglycosides and in intravenous urogra-
phy patients, the IAP/creatinine ratios were also increased. These
IAP/creatinine elevations may reflect cellular events at the level of the
S3 segment, known to be a preferential area of the proximal tubule,
subject to drug toxicity.
Low molecular weight proteins (LMWP) as carriers for renal drug
targeting. D. de Zeeuw, E.J.F. Franssen, F. Moolenaar, J. Visser,
D.K.F. Meyer, Departments of Nephrology and Pharmacology, Uni-
versity of Groningen, The Netherlands. LMWP's, such as lysozyme,
are almost freely filtered through the renal glomerular basement mem-
brane (GBM) and subsequently nearly completely reabsorbed and
hydrolyzed by the proximal tubular cells. In theory this should make
LMWP's suitable carriers for site-specific delivery of drugs to the
kidney. To test this hypothesis we covalently coupled the non-steroidal-
anti-inflammatory drug naproxen to egg white lysozyme, and injected
10 mg of this conjugate iv. in 6 rats. The experimental setting allowed
blood and urine sampling of these freely moving rats. The pharmaco-
kinetic profile of the conjugate was compared with that obtained after
injection of similar amounts of uncoupled naproxen and lysozyme.
Plasma clearance of the naproxen-lysozyme conjugate closely resem-
bled that of lysozyme itself 1.l and 1.2 mI/mm; t½, 85 and 75 mm,
respectively). In case of uncoupled naproxen-lysozyme mixture plasma
levels of naproxen could be measured immediately after i.v. injection of
the mixture. A subsequent plasma disappearence of naproxen was
observed with a t½ of 3.5 hr. coinciding with urinary excretion of
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naproxen metabolites (mainly 6-desmethyl-naproxen-sulphate) between
0 and 12 hrs after injection. In contrast, after injection of covalently
bound naproxen, plasma levels of the parent drug were below the
detection level, whereas naproxen metabolites were abundantly present
in the urine from 4 up to 120 hrs. Apparently, the kidneys are able to
take up the conjugate and hydrolyze the supposed amide bond between
naproxen and lysozyme. We conclude that naproxen pharmacokinetics
are altered by covalent coupling of the drug to lysozyme, such that
"free" naproxen is not detectable in plasma whereas urinary excretion
shows a local sustained release" profile. Thus, LMWP's or other
polypeptides (which freely pass the GBM) may be of use for specific
renal delivery of drugs or diagnostic agents.
